Search
Phosphocreatine
go.drugbank.com/drugs/DB13191InvestigationalNutraceuticalIt is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Clavulanic acid
go.drugbank.com/drugs/DB00766ApprovedInvestigationalVet approved[A182228]When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.[L7880,L7904,L7910]
Mixtures: Clavulin 125 F Oral Sus, Clavulin 250 F Oral SusCilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalIt is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.
Flecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawn[A186931] It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter. … [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.
Products: FLECAINIDE DOC GENERICIClobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions
Borage oil
go.drugbank.com/drugs/DB11238ApprovedBorage oil is used as an herbal treatment of skin disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although … GLA, which accounts for approximately 24% of the oil, is converted to dihomo-γ-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series
Ustekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigational[A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … Ustekinumab biosimilars are available in some markets, including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[
Carbazochrome
go.drugbank.com/drugs/DB09012ApprovedWithdrawnIt is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries.
Lornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of...